Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2
- PMID: 1596225
- DOI: 10.1001/archopht.1992.01080180052028
Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2
Abstract
Between September 1987 and October 1990, 265 eyes with rhegmatogenous retinal detachment and severe (with a classification of at least C-3) proliferative vitreoretinopathy were treated with vitrectomy and randomized to treatment with perfluoropropane gas or silicone oil; 131 eyes had undergone no prior vitrectomy (group 1) while 134 eyes had undergone vitrectomy with intraocular gas tamponade (group 2). At the last examination, there were no differences between perfluoropropane gas and silicone oil in achieving visual acuity greater than or equal to 5/200 (43% vs 45% for group 1, 38% vs 33% for group 2) and complete posterior retinal reattachment (73% vs 64% for group 1, 73% vs 61% for group 2). For group 1 eyes followed up for at least 18 months, there was an advantage favoring perfluoropropane gas in achieving complete posterior retinal reattachment (83% vs 60% at 36 months, P = .045). The rates of reoperation and keratopathy were similar, while hypotony was more prevalent in eyes randomized to perfluoropropane gas (group 2). Regardless of tamponade, groups 1 and 2 had similar anatomic and visual success. However, hypotony was twice as prevalent in group 2 (perfluoropropane), and the prevalence of keratopathy increased with follow-up in group 2 (either tamponade). Either tamponade produced better results than those seen with sulfur hexafluoride gas (Silicone Study Report 1).
Comment in
-
Oil and gas on troubled waters. The proliferative vitreoretinopathy studies.Arch Ophthalmol. 1992 Jun;110(6):768-9. doi: 10.1001/archopht.1992.01080180040026. Arch Ophthalmol. 1992. PMID: 1596223 No abstract available.
-
Silicone oil vs perfluoropropane gas as a postoperative retinal tamponade.Arch Ophthalmol. 1994 Jun;112(6):728-9. doi: 10.1001/archopht.1994.01090180026005. Arch Ophthalmol. 1994. PMID: 8002822 No abstract available.
-
Reports by the Silicone Study Group.Arch Ophthalmol. 1993 Apr;111(4):428; author reply 429. doi: 10.1001/archopht.1993.01090040018006. Arch Ophthalmol. 1993. PMID: 8470962 Clinical Trial. No abstract available.
Similar articles
-
Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1.Arch Ophthalmol. 1992 Jun;110(6):770-9. doi: 10.1001/archopht.1992.01080180042027. Arch Ophthalmol. 1992. PMID: 1596224 Clinical Trial.
-
Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11.Arch Ophthalmol. 1997 Mar;115(3):335-44. doi: 10.1001/archopht.1997.01100150337005. Arch Ophthalmol. 1997. PMID: 9076205 Clinical Trial.
-
Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 3.Retina. 1993;13(4):279-84. doi: 10.1097/00006982-199313040-00002. Retina. 1993. PMID: 8115726 Clinical Trial.
-
Pars Plana Vitrectomy With Silicone Oil or Gas Tamponade for Uncomplicated Retinal Detachment: A Systematic Review and Meta-Analysis.Am J Ophthalmol. 2024 Oct;266:144-155. doi: 10.1016/j.ajo.2024.05.008. Epub 2024 May 28. Am J Ophthalmol. 2024. PMID: 38815844
-
[Treatment of vitreoretinal proliferation in rhegmatogenous detachment and silicone oil tamponade].J Fr Ophtalmol. 1996;19(2):97-105. J Fr Ophtalmol. 1996. PMID: 8731777 Review. French.
Cited by
-
Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study.Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1193-8. doi: 10.1007/s00417-010-1389-7. Epub 2010 Apr 28. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20424852 Clinical Trial.
-
Re-vitrectomy for recurrent retinal detachment in post-vitrectomy eyes of rhegmatogenous retinal detachment.BMC Ophthalmol. 2022 Nov 16;22(1):439. doi: 10.1186/s12886-022-02665-8. BMC Ophthalmol. 2022. PMID: 36384489 Free PMC article.
-
Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy.Jpn J Ophthalmol. 2010 Jul;54(4):331-7. doi: 10.1007/s10384-010-0807-z. Epub 2010 Aug 11. Jpn J Ophthalmol. 2010. PMID: 20700802
-
The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy.PLoS One. 2013 Dec 9;8(12):e82283. doi: 10.1371/journal.pone.0082283. eCollection 2013. PLoS One. 2013. PMID: 24349246 Free PMC article.
-
Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy.Eye (Lond). 2014 May;28(5):576-80. doi: 10.1038/eye.2014.21. Epub 2014 Feb 21. Eye (Lond). 2014. PMID: 24556886 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous